Profound Medical Corp. (PROF)

NASDAQ: PROF · Real-Time Price · USD

6.69

-0.06 (-0.89%)

At close: Apr 28, 2026, 4:00 PM EDT

6.70

+0.01 (0.15%)

After-hours: Apr 28, 2026, 4:10 PM EDT

-0.89% (1D)

Market Cap	247.34M
Revenue (ttm)	16.10M
Net Income (ttm)	-42.57M
Shares Out	36.29M
EPS (ttm)	-1.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,694
Open	6.74
Previous Close	6.75
Day's Range	6.51 - 6.91
52-Week Range	3.76 - 8.95
Beta	0.47
Analysts	Strong Buy
Price Target	12.00 (+79.37%)
Earnings Date	May 7, 2026

About PROF

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-t... [Read more]

Industry Medical Devices

Sector Healthcare

CEO Arun Menawat

Employees 162

Stock Exchange NASDAQ

Ticker Symbol PROF

Website https://www.profoundmedical.com

Full Company Profile

Financial Performance

In 2025, Profound Medical's revenue was $16.10 million, an increase of 50.73% compared to the previous year's $10.68 million. Losses were -$42.57 million, 53.0% more than in 2024.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PROF stock is "Strong Buy" and the 12-month stock price target is $12.0.

Price Target

$12.0

(79.37% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Profound Medical Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

TULSA, an AI-driven, MRI-guided, incision-free prostate therapy, is gaining traction with strong clinical data, expanding insurance coverage, and a growing addressable market in prostate cancer and BPH. High margins and partnerships with major MRI companies support robust financial growth.

6 days ago - Transcripts

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are ad...

7 days ago - GlobeNewsWire

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...

14 days ago - GlobeNewsWire

Profound Medical Corp. Investigated by the Portnoy Law Firm

LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Profound Medical Corp. , (“ Profound " or the "Company") ( NASDAQ : PROF) investors that the firm has initiated an investi...

19 days ago - GlobeNewsWire

Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...

27 days ago - GlobeNewsWire

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...

4 weeks ago - GlobeNewsWire

Top 3 Health Care Stocks That Are Set To Fly In March

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

5 weeks ago - Benzinga

Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes

6 weeks ago - GuruFocus

Profound Medical Transcript: Status update

Six-month CAPTAIN trial data show TULSA outperforms surgery in safety and functional recovery for intermediate-risk prostate cancer, with rapid patient recovery and strong quality-of-life outcomes. TULSA's inclusion in the 2025 NCCN guidelines and robust evidence base position it for broader adoption and payer coverage as further oncologic data matures.

6 weeks ago - Transcripts

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment –

6 weeks ago - GlobeNewsWire

Profound Medical (PROF) Awaits Key Clinical Data Presentation

7 weeks ago - GuruFocus